Clinical trials: Sintilimab
Stereotactic Body Radiotherapy, PD-1 Inhibitors
Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer
The goal of this observational study is to investigate the efficacy and safety of stereotactic body radiotherapy combined with PD-1 blockers for LAPC and LRPC.
- Conditions
- Stereotactic Body Radiotherapy, PD-1 Inhibitors, Pancreatic Cancer
- Trial name
- NCT06195254
- Testing
- Stereotactic body radiotherapy (SBRT), PD-1 blocking antibody
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Peking University Third Hospital
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Lung Squamous Cell Carcinoma
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter phase II clinical trial comparing the efficacy and safety of low-dose radiation therapy and stereotactic body radiation therapy combined with PD-1 inhibitor (sintilimab)…
- Trial name
- NCT06121505
- Testing
- low-dose radiation therapy and stereotactic body radiation therapy, chemotherapy, Sintilimab
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Sichuan University
Liver Cancer
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Targeted Therapy and a PD-1 Inhibitor in Patients with Postoperative Hepatocellular Carcinoma…
- Trial name
- NCT07790419
- Testing
- HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhai Wenlong
Astrocytoma of Brain
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05518994
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Provincial People's Hospital
NSCLC, Neoadjuvant Immunotherapy
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
To evaluate efficacy and safety of low dose radiotherapy combined with sintilimab and platinum based chemotherapy as neoadjuvant therapy for stage II-III Non-Small Cell Lung Cancer
- Conditions
- NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
- Trial name
- NCT06714708
- Testing
- Experimental, Active comparator
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Anhui Provincial Cancer Hospital
Non Small Cell Lung Cancer
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Exploring the efficacy of PD-1 inhibitor combination therapy strategies for adjuvant therapy in a population that has not achieved major pathological regression after neoadjuvant immunotherapy for non-small cell lung cancer: a…
- Trial name
- NCT06620822
- Testing
- IBI363, LM-108+Sintilimab, IBI310+Sintilimab
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC Stage IV
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.
- Trial name
- NCT04106180
- Testing
- GM-CSF, Sintilimab, SBRT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Fudan University
Renal Cell Carcinoma, FH-deficient
Sintilimab in FH-deficient Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma.
- Conditions
- Renal Cell Carcinoma, FH-deficient, Sintilimab
- Trial name
- NCT04146831
- Testing
- Sintilimab
- Volunteers
- 37 people
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab alone based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm )…
- Trial name
- NCT05088967
- Testing
- IBI110, sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Biliary Tract Cancer
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
This is a randomized, noncomparative, open-label, exploratory clinical study designed to evaluate the efficacy and safety of sintilimab in combination with NALIRIFOX or gemcitabine plus cisplatin (GP) as first-line treatment for…
- Trial name
- NCT07831993
- Testing
- Sintilimab, Irinotecan Hydrochloride Liposome Injection (II), Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreas Cancer
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in…
- Trial name
- CISPD-7 (NCT06572813)
- Testing
- Bortezomib Injection, Sintilimab, mFOLFIRINOX
- Where
- China
- Volunteers
- 63 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hepatocellular Carcinoma (HCC)
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular…
- Trial name
- NCT07422753
- Testing
- CTLA-4 Antibody(ipilimumab N01)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Esophageal Squamous Cell Carcinoma
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT06138028
- Testing
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao Central Hospital
Chronic Hepatitis B
Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B
This is a prospective, multicenter, randomized, open-label controlled clinical trial designed to evaluate the efficacy and safety of a sequential treatment strategy incorporating a PD-1 antibody and pegylated interferon-α…
- Trial name
- NCT07809165
- Testing
- Sintilimab, Pegylated Interferon-α 2b, Nucleos(t)ide Analogues
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Gastric Cancer, GastroEsophageal Cancer
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion. The main question is aim to answer is: 1.
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
- Trial name
- NCT06241469
- Testing
- Sintilimab,nab-paclitaxel and tegio
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Wu Jun
Pathological Complete Response, Rectal Cancer
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
This study is designed as a single-center, phase II exploratory clinical trial to evaluate the pathological response rate and safety of sintilimab (PD-1 inhibitor) combined with XELOX regimen (oxaliplatin + capecitabine) for…
- Conditions
- Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07127497
- Testing
- Sintilimab combined with XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Gastric Cancer Peritoneal Metastases
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
- Trial name
- NCT06487715
- Testing
- albumin-bound paclitaxel (260 mg/m2, d1), S-1, sintilimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nasopharyngeal Carcinoma (NPC)
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma.
- Trial name
- NCT06680115
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital